It doesn’t matter how well a drug kills cancer cells if the patient doesn’t stay on treatment. Side effects lead many patients to interrupt dosing of a drug regimen, allowing cancer to advance, said ...

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological ...

Adagene Inc. announced promising results from its Phase 1b/2 study of the CTLA-4 inhibitor ADG126 in patients with advanced microsatellite stable colorectal cancer (MSS CRC) without liver metastases.

27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels of ...

These findings may not be generalizable to uninsured patients with ovarian cancer, who face unique barriers to care compared with insured patients. Your study found no significant differences in ...

As individuals, we can’t do much about microplastics. A lot of it ends up in the oceans, the fish are ingesting it and we’re ...

WALTHAM, Mass., May 31, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for ...

WALTHAM, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people ...